You are here

Scheduling delegate's final decisions: Cannabis, May 2017

Scheduling medicines and poisons

31 May 2017

Book pagination

Summary of delegate's final decisions

Part A - Final decisions on matters referred to an expert advisory committee

1. Scheduling proposals referred to the November 2016 meeting of the Joint Advisory Committee on Chemicals and Medicines Scheduling (ACCS-ACMS#14)

Summary of delegate's final decisions
Substance Final decision
Cannabis, tetrahydrocannabinols and cannabidiol

Schedule 9 - Current Entry

CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:

  1. when separately specified in these Schedules; or
  2. processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
  3. in hemp seed oil for purposes other than internal human use containing 50 mg/kg or less of cannabinoids.

Schedule 8 - Current Entry

# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:

  1. cultivated or produced, or in products manufactured , in accordance with the Narcotic Drugs Act 1967; and/or
  2. for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
  3. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
  4. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,

except when:

  1. it is a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
  2. separately specified in Schedule 4; or
  3. separately specified in the NABIXIMOLS entry in this Schedule; or
  4. in hemp seed oil for purposes other than internal human therapeutic use containing 50 mg/kg or less of cannabinoids.

Schedule 9 - Amend Entry

TETRAHYDROCANNABINOLS and their alkyl homologues, except:

  1. when included in Schedule 4 or Schedule 8; or
  2. processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
  3. in hemp seed oil containing 50 mg/kg or less of tetrahydrocannabinols when labelled with either of the following warning statements:
    1. Not for internal use; or
    2. Not to be taken; or

Schedule 8 - Amend Entry

# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:

  1. included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
  2. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
  3. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,

except when:

  1. it is a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
  2. in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with either of the following warning statements:
    1. Not for internal use; or
    2. Not to be taken; or
  3. separately specified in the NABIXIMOLS entry in this Schedule.

Schedule 4 - Current Entry

CANNABIDIOL in preparations for therapeutic use containing 2 per cent or less of other cannabinoids found in cannabis.

Appendix D, Item 1 - Current Entries

CANNABIS

TETRAHYDROCANNABINOLS

Implementation date of 1 October 2017

Schedule 9 - Amend Entry

CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:

  1. when separately specified in these Schedules; or
  2. processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
  3. in hemp seed oil for purposes other than internal human use containing 50 mg/kg or less of total cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols, when labelled with either of the following warning statements:
    1. Not for internal use; or
    2. Not to be taken.

Schedule 8 - Amend Entry

# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:

  1. cultivated or produced, or in products manufactured[2], in accordance with the Narcotic Drugs Act 1967; and/or
  2. for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
  3. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
  4. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,

except when:

  1. it is a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
  2. separately specified in Schedule 4; or
  3. separately specified in the NABIXIMOLS entry in this Schedule.

Schedule 9 - Amend Entry

TETRAHYDROCANNABINOLS and their alkyl homologues, except:

  1. when included in Schedule 4 or Schedule 8; or
  2. processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
  3. in hemp seed oil for purposes other than internal human use containing 50 mg/kg or less of total cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols, when labelled with either of the following warning statements:
    1. Not for internal use; or
    2. Not to be taken.

Schedule 8 - Amend Entry

# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:

  1. included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
  2. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
  3. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,

except when:

  1. it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
  2. separately specified in the NABIXIMOLS entry in this Schedule.

Schedule 4 - Amend Entry

CANNABIDIOL in preparations for therapeutic use containing 2 per cent or less of total other cannabinoids found in cannabis.

APPENDIX D, ITEM 1 - Current entries

CANNABIS for human use.

TETRAHYDROCANNABINOLS for human use.

APPENDIX K - Current entries

CANNABIS

TETRAHYDROCANNABINOLS

Index - Amend entries

CANNABICHROMENE
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIOLIC ACID
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIVAROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIGEROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOIDS
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIS
cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS

TETRAHYDROCANNABINOLIC ACID
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

TETRAHYDROCANNABINOLS
cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS

TETRAHYDROCANNABIDIVAROL
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

Implementation date of 1 June 2018.


Footnote

  1. "Cultivation", "production" and "manufacture" have the same meaning as in the Narcotic Drugs Act 1967
  2. "Cultivation", "production" and "manufacture" have the same meaning as in the Narcotic Drugs Act 1967

Book pagination